166 related articles for article (PubMed ID: 35675354)
1. Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Guardado Rivas MO; Stuart SD; Thach D; Dahan M; Shorr R; Zachar Z; Bingham PM
PLoS One; 2022; 17(6):e0269620. PubMed ID: 35675354
[TBL] [Abstract][Full Text] [Related]
2. The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner.
Arnold C; Demuth P; Seiwert N; Wittmann S; Boengler K; Rasenberger B; Christmann M; Huber M; Brunner T; Linnebacher M; Fahrer J
Mol Cancer Ther; 2022 Jan; 21(1):100-112. PubMed ID: 34750196
[TBL] [Abstract][Full Text] [Related]
3. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo.
Zachar Z; Marecek J; Maturo C; Gupta S; Stuart SD; Howell K; Schauble A; Lem J; Piramzadian A; Karnik S; Lee K; Rodriguez R; Shorr R; Bingham PM
J Mol Med (Berl); 2011 Nov; 89(11):1137-48. PubMed ID: 21769686
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Pardee TS; Lee K; Luddy J; Maturo C; Rodriguez R; Isom S; Miller LD; Stadelman KM; Levitan D; Hurd D; Ellis LR; Harrelson R; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2014 Oct; 20(20):5255-64. PubMed ID: 25165100
[TBL] [Abstract][Full Text] [Related]
5. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling.
Gao L; Xu Z; Huang Z; Tang Y; Yang D; Huang J; He L; Liu M; Chen Z; Teng Y
J Exp Clin Cancer Res; 2020 Apr; 39(1):73. PubMed ID: 32345326
[TBL] [Abstract][Full Text] [Related]
6. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism.
Lee KC; Shorr R; Rodriguez R; Maturo C; Boteju LW; Sheldon A
Drug Metab Lett; 2011 Aug; 5(3):163-82. PubMed ID: 21722089
[TBL] [Abstract][Full Text] [Related]
7. An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio).
Hala D; Faulkner P; He K; Kamalanathan M; Brink M; Simons K; Apaydin M; Hernout B; Petersen LH; Ivanov I; Qian X
Comp Biochem Physiol C Toxicol Pharmacol; 2021 Oct; 248():109084. PubMed ID: 34051378
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Mitochondrial Metabolism Leads to Selective Eradication of Cells Adapted to Acidic Microenvironment.
Koncošová M; Vrzáčková N; Křížová I; Tomášová P; Rimpelová S; Dvořák A; Vítek L; Rumlová M; Ruml T; Zelenka J
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639130
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma.
Egawa Y; Saigo C; Kito Y; Moriki T; Takeuchi T
PLoS One; 2018; 13(6):e0198940. PubMed ID: 29879220
[TBL] [Abstract][Full Text] [Related]
11. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy.
Tan Z; Xiao L; Tang M; Bai F; Li J; Li L; Shi F; Li N; Li Y; Du Q; Lu J; Weng X; Yi W; Zhang H; Fan J; Zhou J; Gao Q; Onuchic JN; Bode AM; Luo X; Cao Y
Theranostics; 2018; 8(9):2329-2347. PubMed ID: 29721083
[TBL] [Abstract][Full Text] [Related]
12. Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.
Kumstel S; Schreiber T; Goldstein L; Stenzel J; Lindner T; Joksch M; Zhang X; Wendt EHU; Schönrogge M; Krause B; Vollmar B; Zechner D
PLoS One; 2022; 17(4):e0266601. PubMed ID: 35452495
[TBL] [Abstract][Full Text] [Related]
13. Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant Carcinomas.
Bingham PM; Zachar Z
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762668
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human.
Reddy VB; Boteju L; Boteju A; Shen L; Kassahun K; Reddy N; Sheldon A; Luther S; Hu K
Drug Metab Dispos; 2022 Apr; 50(4):361-373. PubMed ID: 35086846
[TBL] [Abstract][Full Text] [Related]
15. c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate.
Edmunds LR; Sharma L; Kang A; Lu J; Vockley J; Basu S; Uppala R; Goetzman ES; Beck ME; Scott D; Prochownik EV
J Biol Chem; 2014 Sep; 289(36):25382-92. PubMed ID: 25053415
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation.
Tsai YT; Lo WL; Chen PY; Ko CY; Chuang JY; Kao TJ; Yang WB; Chang KY; Hung CY; Kikkawa U; Chang WC; Hsu TI
J Biomed Sci; 2022 Mar; 29(1):21. PubMed ID: 35337344
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation.
Oppermann H; Schnabel L; Meixensberger J; Gaunitz F
Oncotarget; 2016 Dec; 7(52):85848-85860. PubMed ID: 27811375
[TBL] [Abstract][Full Text] [Related]
18. Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.
Tyszka-Czochara M; Konieczny P; Majka M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230778
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of an LC-MS/MS method for determination of a novel anticancer agent (CPI-613) in human plasma.
Reddy NR; Reddy V; Boteju A; Boteju L; Voelker T; Liu S; Hu K
Bioanalysis; 2022 Mar; 14(5):253-266. PubMed ID: 35172610
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
